Pfizer Incorporated (NYSE: PFE) is a pharmaceutical company, ranking number one in sales in the world. The company is based in New York City, with its research headquarters in Groton, Connecticut. It produces Lipitor (atorvastatin, used to lower blood cholesterol); the neuropathic pain/fibromyalgia drug Lyrica (pregabalin); the oral antifungal medication Diflucan (fluconazole), the antibiotic Zithromax (azithromycin), Viagra (sildenafil) for erectile dysfunction, and the anti-inflammatory Celebrex (celecoxib) (also known as Celebra in some countries outside the USA and Canada, mainly in South America). Its headquarters are in Midtown Manhattan, New York City.

Source: Wikipedia

Campaign Finance

Information

Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:

  • contributions under $200 are not reported, and so are not included in totals.
  • only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
  • contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
  • corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
  • organization totals include known subsidiaries of the organization.

For more information, please see our campaign finance methodology page. Lobbyist bundling data is described on our lobbyist bundling methodology page.

Latest FEC Data

covers through committee's April 8, 2011 filing.
Download all contributions to Pfizer Inc

  • Summary

    overview of the committee's finances
    Total Raised:
    $1,855,628
    Total Spent:
    $2,009,857
    Cash on Hand:
    $402,001
    Debts:
    $0

Standardized Donation Information

covers through 2011. may lag behind FEC section above, as donors and industries are identified by hand.

  • Top Recipients

    Employee Color Block
    Individuals
    PAC Color Block
    PAC
    Includes contributions from the organization’s employees, their family members, and its political action committee.

  • Republicans vs. Democrats

    in dollars. "Other" includes 3rd parties and organizations without official party affiliation.

  • State vs. Federal

    in dollars

  • Top PAC Recipients

    Employee Color Block
    Individuals
    PAC Color Block
    PAC
    Includes contributions from the organization’s employees, their family members, and its political action committee.
View all campaign finance data for Pfizer Inc Sources: OpenSecrets.org FollowTheMoney.org

Lobbying

$10,700,000 Spent
Information

Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.

For more information, please see our lobbying methodology page.

covers through Q3, 2011

Lobbying On Behalf of Pfizer Inc

View all lobbying data for Pfizer Inc Sources: OpenSecrets.org

Regulations

53 Mentions; 6 Submissions
Information

All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.

Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.

Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.

Regulations and public comments can be downloaded in bulk here.

updated from Regulations.gov on September 27, 2011

The tables show occurrences of "Pfizer Inc" in public comments on proposed federal regulations.

  • Documents Submitted by the Organization
    • Submissions
    • Agency
    • Docket
    • Date
    • Toggle 1 FDA Draft Guidance for Industry on Non-Penicillin Beta-Lactam Risk Assessment: A CGMP Framework; Availability 2011
    • Toggle 1 FDA Biologics Price Competition and Innovation Act of 2009; Options for a User Fee Program for Biosimilar and Interchangeable Biological Product Applications for Fiscal Years 2013 through 2017; Request for Comments 2011
    • Toggle 1 FDA International Conference on Harmonisation; Draft Guidance on Q11 Development and Manufacture of Drug Substances; Availability 2011
    • Toggle 1 FDA Draft Guidance for Industry on Clinical Pharmacogenomics: Premarketing Evaluation in Early Phase Clinical Studies; Availability 2011
    • Toggle 1 FDA Establish Comprehensive, Clear and Binding Regulations to Guide The Industry Relating to New Uses of Marketed Drugs and Medical Devices 2011
    • Toggle 1 FDA Draft Guidance for Industry and FDA Staff on Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets; Availability 2011
  • Mentions in Document Text
    • Mentions
    • Agency
    • Docket
    • Date
    • Toggle 10 FDA Determine That Pfizer's Antivert® Chewable Tablets 25 mg was not Discontinued for Safety and Efficacy Reason and re List InvaGen's Meclizine Hydrochloride Chewable Tablets, 25 mg 2011
    • Toggle 6 FDA NADA/ANADA Notices 2011
    • Toggle 2 ITA Request for Public Comments Concerning Regulatory Cooperation Activities that Would Help Eliminate or Reduce Unnecessary Regulatory Divergences in North America that Disrupt U.S. Exports 2011
    • Toggle 2 FDA Agency Information Collection Activities; Proposed Collection; Comment Request; Infant Formula Label Statements Experimental Study 2011
    • Toggle 2 FDA Patent Term Extension Application for Prevnar 13®, U.S. Patent No.5,614,382 2011
    • Toggle 2 FDA International Conference on Harmonisation; Draft Guidance on Q11 Development and Manufacture of Drug Substances; Availability 2011
    • Toggle 2 FDA Permit the Filing of an Abbreviated New Animal Drug Application for (Marbofloxacin) Chewable Tablet Formulation in Strengths of 25 mg, 50 mg, 100 mg and 200 mg - CLOSED 2011
    • Toggle 2 FDA Advisory Committee, Workshops, and Conferences Notices Various Meeting Notices (eg., Task Force Meeting, etc.) 2011
    • Toggle 2 FDA Periodic Review of Existing Regulations; Retrospective Review Under Executive Order 13563 2011
    • Toggle 2 FDA Animal Drugs, Feeds, and Related Products; Withdrawal of Approval of New Animal Drug Applications; Chorionic Gonadotropin, Cuprimyxin, Diethylcarbamazine; Levamisole, Nitrofurazone, Phenylbutazone; Pyrantel; Tylosin; Tylosin and Sulfamethazine. 2011

Federal Spending

7 contracts
Information

Federal grants, contracts and loans are reported by federal agencies using the FPDS and FAADS systems. The data is made available to the public at USASpending.gov. Please note that the completeness and quality of the data varies greatly by agency.

Only grants, contracts and loans with amounts over $1 million are shown.

Because company names are not reported in a standardized manner, we cannot reliably determine the company receiving the contract or award. The results shown here are based on a search for the company name. Individual records may be missed or erroneously included because of name variations. For more information, please see our federal spending methodology page.

covers through USASpending.gov's March 1, 2012 release

Note: Company names in federal spending data are not standardized. The table below is included only as a sample of what is available in the data and has not been reviewed for accuracy or completeness. To investigate the data further, use the links at the bottom of the table.

Type Recipient Name Year Agency Description Amount
contract
 Pfizer Inc. 2012 Centers For Disease Control PFIZER VFC 2011 $287,552,818
contract
 Pfizer Inc. 2011 Centers For Disease Control VACCINE FOR CHILDREN 2011 $281,640,506
contract
 Pfizer Inc. 2012 Centers For Disease Control PFIZER VFC 2011 $131,240,596
contract
 Pfizer Inc. 2011 Centers For Disease Control PFIZER VFC 2011 $111,038,414
contract
 Pfizer Inc. 2011 Centers For Disease Control VACCINE FOR CHILDREN 2011 $103,135,727
contract
 Pfizer Inc. 2011 Centers For Disease Control PFIZER VFC 2011 $92,835,550
contract
 Pfizer Inc. 2011 Centers For Disease Control PFIZER VFC 2011 $91,184,535
View all grant & loan data for Pfizer Inc View all contract data for Pfizer Inc Sources: USASpending.gov

Contractor Misconduct

2 Instances
Information

This information is collected by the Project On Government Oversight from press releases, court documents, news reports and other public records. It is not meant to be an exhaustive account of all instances of federal contractor misconduct.

More information on each instance, including primary source documents, is available on POGO's site by clicking on the instance description. More information on POGO's methodology is available here.

covers through POGO's March 3, 2012 release
Misconduct Type Hired By Incident Year Disposition Penalty
Health None U.S. ex rel. Wetherholt and Drimer v. Pfizer (Illegal Marketing of Detrol) 2011 Settlement $14,500,000
Health None Lipitor Webpage Misbranding 2011 Investigative Finding $0
View all contractor misconduct data for Pfizer Inc Sources: Federal Contractor Misconduct Database from POGO

Advisory Committees

8 people on 10 committees
Information

Data is based on disclosures required by the Federal Advisory Committee Act (FACA). Matches are based on the occurrence of the company name in the committee member affiliation. Variations in company names may cause some matches to be missed.

The table shows only the top 10 agencies. To search and download raw records from the complete dataset see the FACA data section.

covers through 2011

Table shows employees of "Pfizer Inc" that sat on federal advisory committees.

  • Agency
  • Representation
  • Toggle Department of Health and Human Services 5 people on 7 committees
  • Toggle Department of Commerce 1 person on 1 committee
  • Toggle Department of State 1 person on 1 committee
  • Toggle National Science Foundation 1 person on 1 committee
View all advisory committee data for Pfizer Inc